Nicox Announces U.S. FDA Acceptance of Investigational New Drug Application for NCX 4251 Phase 2 Trial in Blepharitis
29 January 2019
The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Nicox disavows any obligation to update the information contained in such press releases after the date of their issuance.
04 January 2019
30 October 2018